### Guideline Page and Request

**Internal Request:**
In response to the FDA approval of encorafenib and binimetinib in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, request that the panel vote on encorafenib/binimetinib for this indication.

**External Submission:**
Array Biopharma request to consider the combination of encorafenib/binimetinib as a category 1 option for systemic therapy of metastatic or unresectable disease (ME-H) in the following lines of therapy:
- First-line targeted therapy if a BRAF V600 activating mutation present.
- Second-line or subsequent targeted therapy if a BRAF V600 activating mutation is present.

### Panel Discussion/References

Based on a review of data in the noted reference and the recent FDA approval, the panel consensus was to add encorafenib/binimetinib as a targeted therapy option for metastatic or unresectable disease for patients with BRAF V600 activating mutation, in the following settings:
- **First-line systemic therapy as a category 1 recommendation**
  - Recommendation supported by high-level evidence
- **Second-line or subsequent systemic therapy as a category 2A recommendation**
  - Recommendation supported by high-level evidence


### Vote

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ME-H</strong></td>
<td>22</td>
<td>0</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td><strong>Internal Request:</strong></td>
<td>22</td>
<td>0</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td><strong>External Submission:</strong></td>
<td>16</td>
<td>6</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>